Argomenti e Notizie
con raccolte
bibliografiche su
PubMed Logo
a cura del
Dott. C.Tarozzi
Anno 19°
Num. 122
Recens. 2341
Aderiamo allo standard HONcode per l'affidabilità dell'informazione medica questo sito aderisce fin dal 2004 allo standard HONcode per l'affidabilità dell'informazione medica. Verifica qui.
Rassegna - Alimenti e Calcio - Questionari - T-Score - Valore di un Test - Calcolatori - Contatti - Digitalia - Radioactivity
Ricerca nell'archivio di questo sito...
Nuova bibliografia selezionata fino al mese di giugno 2014 (recensioni 35) Ordina per Autore - Titolo - Rivista
Miyazaki T, Tokimura F, Tanaka S.
A review of denosumab for the treatment of osteoporosis.
Patient Prefer Adherence. 2014 Apr 8;8:463-471.

Maeda SS, Lazaretti-Castro M.
An overview on the treatment of postmenopausal osteoporosis.
Arq Bras Endocrinol Metabol. 2014 Mar;58(2):162-71.

Allan C, Collins VR, Frydenberg M, McLachlan RI, Matthiesson KL.
Androgen deprivation therapy complications.
Endocr Relat Cancer. 2014 May 28.

Reginster JY, Neuprez A, Beaudart C, Lecart MP, Sarlet N, Bernard D, Disteche S, Bruyere O.
Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis.
Drugs Aging. 2014 Jun;31(6):413-24.

Sigua-Rodriguez EA, Da Costa Ribeiro R, De Brito AC, Alvarez-Pinzon N, De Albergaria-Barbosa JR.
Bisphosphonate-Related Osteonecrosis of the Jaw: A Review of the Literature.
Int J Dent. 2014;2014:192320. Epub 2014 Apr 28. Review.

Link TM, Lang TF. Axial QCT:
Clinical Applications and New Developments.
J Clin Densitom. 2014 May 28. pii: S1094-6950(14)00166-8.

Gasparik AI.
Clinical Setting Influences Patterns of Interaction between Osteoporosis Patient and Physician.
Calcif Tissue Int. 2014 May 25. [Epub ahead of print]

Cosman F.
Combination therapy for osteoporosis: a reappraisal.
Bonekey Rep.2014 Apr 2;3:518.

Strong AL, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Burow ME, Bunnell BA, Wang G.
Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells.
ACS Med Chem Lett. 2013 Dec 10;5(2):143-8.

Younes M, Hachfi H, Ben Hammouda S, Jguirim M, Younes K, Zrour S, Bejia I, Touzi M, Bergaoui N.
Discordance between spine and hip Bone Mineral Density measurement using DXA in osteoporosis diagnosis: Prevalence and risk factors.
Tunis Med. 2014 Jan;92(1):1-5.

Muraki S, Akune T, Nagata K, Ishimoto Y, Yoshida M, Tokimura F, Tanaka S, Kawaguchi H, Nakamura K, Oka H, Yoshimura N.
Does osteophytosis at the knee predict health-related quality of life decline? A 3-year follow-up of the ROAD study.
Clin Rheumatol. 2014 May 30. [Epub ahead of print]

Brown JP, Reid IR, Wagman RB, Kendler D, Miller PD, Jensen JE, Bolognese MA, Daizadeh N, Valter I, Zerbini CA, Dempster DW.
Effects of up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension.
J Bone Miner Res. 2014 Apr 1.

Lems WF, Geusens P.
Established and forthcoming drugs for the treatment of osteoporosis.
Curr Opin Rheumatol. 2014 May;26(3):245-51.

Cooper C, Fox KM, Borer JS.
Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD.
Osteoporos Int. 2014 Feb;25(2):737-45.

Farooki A.
NCCN Bone Health Task Force: Key Recommendations.
J Natl Compr Canc Netw. 2014 May;12(5 Suppl):813-6.

Abrahamsen B, Grove EL, Vestergaard P.
Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate.
Osteoporos Int. 2014 Feb;25(2):757-62.

Gong B, Mandair GS, Wehrli FW, Morris MD.
Novel Assessment Tools for Osteoporosis Diagnosis and Treatment.
Curr Osteoporos Rep. 2014 May 31. [Epub ahead of print]

Gupta S, Ahsan I, Mahfooz N, Abdelhamid N, Ramanathan M, Weinstock-Guttman B.
Osteoporosis and Multiple Sclerosis: Risk Factors, Pathophysiology, and Therapeutic Interventions.
CNS Drugs. 2014 May 29. [Epub ahead of print]

Gerdhem P.
Osteoporosis and fragility fractures.
Best Pract Res Clin Rheumatol. 2013 Dec;27(6):743-755. Review.

Shah D, Nagarajan N.
Premature menopause - Meeting the needs.
Post Reprod Health. 2014 May 16.

Appelman-Dijkstra NM, Papapoulos SE.
Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches.
Best Pract Res Clin Rheumatol. 2013 Dec;27(6):805-820.

Mehra A.
Reinventing the general practitioner menopause clinic - personal experiences.
Post Reprod Health. 2014 May 20. pii:

Fernández JM, Molinuevo MS, McCarthy AD, Cortizo AM.
Strontium ranelate stimulates the activity of bone-specific alkaline phosphatase: interaction with Zn(2+) and Mg (2+).
Biometals. 2014 Jun;27(3):601-7.

Burch J, Rice S, Yang H, Neilson A, Stirk L, Francis R, Holloway P, Selby P, Craig D.
Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups.
Health Technol Assess. 2014 Feb;18(11):1-180.

Neuprez A, Rompen E, Crielaard JM, Reginster JY.
Teriparatide Therapy for Denosumab-Induced Osteonecrosis of the Jaw in a Male Osteoporotic Patient.
Calcif Tissue Int. 2014 May 8. [Epub ahead of print]

Ganji A, Esmaielzadeh A, Aafzal Aghayee M, Goshayeshi L, Ghaffarzadegan K.
The clinical presentation of celiac disease: experiences from northeastern iran.
Middle East J Dig Dis. 2014 Apr;6(2):93-7.

Rochefort GY.
The osteocyte as a therapeutic target in the treatment of osteoporosis.
Ther Adv Musculoskelet Dis. 2014 Jun;6(3):79-91.

Meier C, Lamy O, Krieg MA, Mellinghoff HU, Felder M, Ferrari S, Rizzoli R.
The role of teriparatide in sequential and combination therapy of osteoporosis.
Swiss Med Wkly. 2014 Jun 4;144:w13952.

Tomková SA, Telepková D, Vanuga P, Killinger Z, Sulková I, Celec P, Payer J.
Therapeutic adherence to osteoporosis treatment.
Int J Clin Pharmacol Ther. 2014 Jun 2.

Lima H, Maia J, Bandeira F.
Trajectories of Bone Remodeling Markers and Bone Mineral Density during Treatment with Strontium Ranelate in Postmenopausal Women Previously Treated with Bisphosphonates.
Clin Med Insights Endocrinol Diabetes. 2014 May 1;7:7-11.

Svanström H, Pasternak B, Hviid A.
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Ann Rheum Dis. 2014 Jun 1;73(6):1037-43.

Vilaça T, Camargo MB, Rocha OF, Lazaretti-Castro M.
Vitamin D supplementation and strontium ranelate absorption in postmenopausal women with low bone mass.
Eur J Endocrinol. 2014 Mar 8;170(4):469-75.

Tenti S, Cheleschi S, Guidelli GM, Galeazzi M, Fioravanti A.
What about strontium ranelate in osteoarthritis? Doubts and securities.
Mod Rheumatol. 2014 Mar 19. [Epub ahead of print]

Hansen KE, Blank RD, Palermo L, Fink HA, Orwoll ES; For The Osteoporotic Fractures In Men (MrOS) Study Research Group.
What analytic method should clinicians use to derive spine T-scores and predict incident fractures in men? Results from the MrOS study.
Osteoporos Int. 2014 May 22. [Epub ahead of print]

Rosales-Aujang E, Muñoz-Enciso JM, Arias-Ulloa R.
[Prevalence of osteopenia and osteoporosis in postmenopausal women and its relation to risk factors].
Ginecol Obstet Mex. 2014 Apr;82(4):223-8. Spanish.

(Vers. 2.1)  Modificato il 6-6-2014   
questo sito aderisce ai principi HONCODE    disclaimer